Pasithea Therapeutics (KTTA) to Present Cancer Treatment Progress at 2025 Conference

Apr 10, 2025

Pasithea Therapeutics Corp. (KTTA, Financial) is set to present important updates on its cancer therapy, PAS-004.
The company will reveal interim safety and efficacy data from its ongoing Phase 1 study.
The focus is on NF1 and patients with MAPK-driven tumors.

Pasithea Therapeutics to Present at CAGLA NeauxCancer Conference

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced plans to present exciting developments regarding its innovative cancer treatment, PAS-004, at the renowned CAGLA NeauxCancer Conference in New Orleans. This anticipated presentation is a key moment for the company as it seeks to showcase its advancements in cancer therapy technologies.

Focus on PAS-004: A Promising Cancer Therapy

The presentation will delve into interim data on the safety and efficacy of PAS-004, derived from an ongoing Phase 1 study. This study specifically targets patients with NF1 and those suffering from MAPK-driven tumors, promising potential breakthroughs in treatment options for these conditions.

Stay updated on the latest developments in the oncology sector by following GuruFocus for more insights and updates on Pasithea Therapeutics and similar companies driving innovation in cancer treatments.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.